Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT01846702 | A Study of LY3084077 in Healthy Participants | PHASE1 | COMPLETED | 43 | — | — | May 1, 2013 | Dec 1, 2013 | Jul 30, 2018 | 1 | Singapore |
An SAE is an adverse event that results in death, persistent or significant disability/incapacity, or drug dependency/abuse; is life-threatening, an important medical event, or a congenital anomaly/birth defect; or requires or prolongs hospitalization. A summary of other non-serious adverse events and all serious adverse events, regardless of causality, is located in the Reported Adverse Events Section.
| Arm | Type | Description |
|---|---|---|
| Placebo | PLACEBO_COMPARATOR | Single dose of placebo matching LY3084077 administered subcutaneously (SC). |
| LY3084077 | EXPERIMENTAL | Single escalating doses (1 mg up to 300 mg) of LY3084077 administered SC. |
| Name | Type | Description |
|---|---|---|
| Placebo | DRUG | Given as a SC injection. |
| LY3084077 | DRUG | Given as a SC injection. |
Inclusion Criteria: * Have normal blood pressure * Must be a healthy male or female who cannot become pregnant * Have a body mass index (BMI) of 18.5 to 40.0 kg/m\^2, inclusive, at screening Exclusion Criteria: * Have known allergies to fibroblast growth factor-21 (FGF21) analogues, glucagon-like...